Company
As a start-up focusing on research, our goal is not only to improve melanoma diagnostics, but to provide effective support for other skin tumors and diseases.
Magnosco
We are facing new tasks to implement what we have learned and to pursue new research approaches.
Before expanding our market activity, our first priority is further development of the device.
In this phase we are completely dedicated to development and will not place any further devices on the market. The existing DermaFCs will be used for research purposes. Commercial use is not possible at this point.
Next Steps
We are facing new tasks to implement what we have learned and to pursue new research approaches.
Before expanding our market activity, our first priority is further development of the device.
In this phase we are completely dedicated to development and will not place any further devices on the market. The existing DermaFCs will be used for research purposes. Commercial use is not possible at this point.
Our Team
Our managing directors Thomas Diepold and Dr. Sebastian Ahlberg lead the team of engineers, developers and scientists.
Our team
Working at magnosco
Are you looking for an exciting job at an innovative healthcare start-up? Are laser spectroscopy and artificial intelligence no foreign words for you?
Then you've come to the right place
Certificates & Compliance
Magnosco GmbH is DIN EN ISO 13485:2016
certified
Contact
Magnosco GmbH
Justus-von-Liebig-Straße 2
DE-12489 Berlin
+49 (0)30 912075 357
Email to magnsoco